

Table 1: Plasma EBV DNA status at the first round of screening for NPC patients identified at the second round of screening

Plasma EBV DNA status at the first round of screening	Total no. of participants	No. of cases of NPC identified in second round of screening	Percentage of participants with NPC identified in the second round of screening	Relative risk
Negative	16,924	17	0.100%	1.0
*Transient	677	3	0.443%	4.4
Persistent	237	4	1.688%	16.8

*Participants with detectable plasma EBV DNA at baseline that became undetectable four weeks later in the follow-up test